MediciNova: Leading The Pack In An MS Subtype [Seeking Alpha]
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: Seeking Alpha
MediciNova: Leading The Pack In An MS Subtype Summary MNOV has very strong phase 2b results in a subtype of MS for its lead candidate. It also has other late-stage trials in fields as diverse as ALS, NASH, etc. Lacking near-term catalysts and trading near 52-week lows, MNOV is a speculative buy. MediciNova, Inc. ( What is the drug MN-166 MN-166 is an immunosuppressive oral small molecule. It is a first-in-class glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6. It may be considered a New Molecular Entity, or NME, in the United States and Europe. However, ibudilast was approved in Japan over 20 years ago. It has been prescribed to over 3.2 million patients and has a good post-marketing safety profile. Global development of MN-166 is in collaboration with Kyorin Pharmaceutical Co., Ltd. of Japan. Catalyst There is no near-term catalyst as of now. The company's pipeline shows, among others, the below indications and the development stage thereof for MN-16
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)GlobeNewswire
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
MNOV
Earnings
- 11/9/23 - Beat
MNOV
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- MNOV's page on the SEC website